



CYPRESS BIOSCIENCE, INC. TO PARTICIPATE IN BIO CEO & INVESTOR CONFERENCE

San Diego, California, February 5, 2010 – **Cypress Bioscience, Inc.** (Nasdaq: CYPB) today announced that Jay D. Kranzler, MD, PhD, its Chairman of the Board and Chief Executive Officer, will participate in a Focus Session titled ‘4th & Goal - Are You Ready To Go Commercial?’ during the BIO CEO & Investor Conference on Tuesday, February 9, 2010. This panel will explore some recent and future strategies and structures used for early stage-product commercialization. The panel session will consist of an interactive panel of companies and industry experts.

The BIO CEO & Investor conference is being held at the Waldorf=Astoria Hotel in New York, NY. The Focus Session during which Dr. Kranzler will speak is scheduled to take place on Tuesday, February 9th at 12:00 p.m. Eastern Time.

About Cypress Bioscience

Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating improved and individualized patient care. Cypress addresses the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders such as fibromyalgia and rheumatoid arthritis. This approach to improving patient care creates a unique partnership with physicians. Current products include Savella® (milnacipran HCl) and the Avise PGSM and Avise MCVSM therapeutic monitoring, diagnostic and prognostic tests for rheumatoid arthritis.

For more information about Cypress, please visit the Company's website at www.cypressbio.com.

For additional information please contact

Mary Gieson, Investor Relations Manager
(858) 452-2323
mgieson@cypressbio.com

###